TY - JOUR
T1 - Neuroleptic malignant syndrome associated with olanzapine
AU - Filice, G. A.
AU - McDougall, B. C.
AU - Ercan-Fang, N.
AU - Billington, C. J.
PY - 1998
Y1 - 1998
N2 - OBJECTIVE: To report a case of neuroleptic malignant syndrome (NMS) associated with the use of olanzapine. CASE SUMMARY: A 67-year-old white man with bipolar disorder developed nausea and vomiting. After 12 days, he became confused, delirious, and manic. His only medications were olanzapine 10 mg/d and divalproex sodium 500 mg bid. He was admitted to a hospital and treated for dehydration and mania. Olanzapine was given on 6 of the first 7 hospital days. On hospital day 6, typical NMS developed with the body temperature increasing to 39.9 °C, obtundation, rigidity, tremor, diaphoresis, fluctuating pupillary diameter, labile tachycardia and hypertension, hypernatremia, and elevated serum creatine kinase. Olanzapine was stopped after hospital day 7, and the syndrome resolved by hospital day 12. DISCUSSION: The patient had all of the major manifestations of NMS. There was no other likely explanation for his illness and he received no other chug likely to be associated with the syndrome. This is the first case reported in which NMS was associated with olanzapine.
AB - OBJECTIVE: To report a case of neuroleptic malignant syndrome (NMS) associated with the use of olanzapine. CASE SUMMARY: A 67-year-old white man with bipolar disorder developed nausea and vomiting. After 12 days, he became confused, delirious, and manic. His only medications were olanzapine 10 mg/d and divalproex sodium 500 mg bid. He was admitted to a hospital and treated for dehydration and mania. Olanzapine was given on 6 of the first 7 hospital days. On hospital day 6, typical NMS developed with the body temperature increasing to 39.9 °C, obtundation, rigidity, tremor, diaphoresis, fluctuating pupillary diameter, labile tachycardia and hypertension, hypernatremia, and elevated serum creatine kinase. Olanzapine was stopped after hospital day 7, and the syndrome resolved by hospital day 12. DISCUSSION: The patient had all of the major manifestations of NMS. There was no other likely explanation for his illness and he received no other chug likely to be associated with the syndrome. This is the first case reported in which NMS was associated with olanzapine.
KW - Neuroleptic malignant syndrome
KW - Olanzapine
UR - http://www.scopus.com/inward/record.url?scp=0031782854&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031782854&partnerID=8YFLogxK
U2 - 10.1345/aph.18151
DO - 10.1345/aph.18151
M3 - Article
C2 - 9825080
AN - SCOPUS:0031782854
SN - 1060-0280
VL - 32
SP - 1158
EP - 1159
JO - Annals of Pharmacotherapy
JF - Annals of Pharmacotherapy
IS - 11
ER -